GemVax&KAEL (082270) Fundamentals 2026 — Revenue Analysis | SniperIQ
GemVax&KAEL (082270) is a KR-listed Industrials company in Industrial - Machinery with a market capitalization of ₩428.1B, trading at ₩9740.00 on the KOE. This SniperIQ fundamentals page covers GemVax&KAEL's valuation, profitability (net margin -4.5%), revenue (₩81.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is GemVax&KAEL's market cap?
GemVax&KAEL (082270) has a market capitalization of approximately ₩428.1B, trading at ₩9740.00 on the KOE. Market cap moves with the live share price.
What is GemVax&KAEL's P/E ratio?
GemVax&KAEL's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.2x. Valuation multiples are best compared with Industrials sector peers rather than read in isolation.
How profitable is GemVax&KAEL?
GemVax&KAEL runs a net profit margin of -4.5%, a gross margin of 40.7%, and an operating margin of 6.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does GemVax&KAEL generate?
GemVax&KAEL reported revenue of ₩81.5B for fiscal year 2025, with net income of -₩11.3B and earnings per share (EPS) of -275. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does GemVax&KAEL pay a dividend?
GemVax&KAEL does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is GemVax&KAEL financially healthy?
GemVax&KAEL carries a debt-to-equity ratio of 0.72x and a current ratio of 1.18x, with a market beta of 0.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is GemVax&KAEL a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For GemVax&KAEL (082270) the key facts are: market cap ₩428.1B, revenue ₩81.5B, 52-week range 9250-61000. Weigh valuation, profitability, growth, and balance-sheet strength against Industrials peers and form your own view.
Track GemVax&KAEL's full fundamentals live
Get GemVax&KAEL's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.